Literature DB >> 17000225

Deep venous thrombosis and pulmonary embolism in hospitalized patients with sickle cell disease.

Paul D Stein1, Afzal Beemath, Frederick A Meyers, Elias Skaf, Ronald E Olson.   

Abstract

BACKGROUND: As would be expected with a hypercoagulable state, pulmonary embolism (PE) occurs in sickle cell disease (SCD). Its frequency, however, is undetermined, largely because of difficulties in distinguishing it from thrombosis in situ. The prevalence of deep venous thrombosis (DVT) is also undetermined in patients with SCD. Knowing the prevalence of DVT would be an important step in the overall assessment of the risk of PE in these patients.
METHODS: Data from the National Hospital Discharge Survey were assessed.
RESULTS: In patients <age 40 years, 7000 of 1,581,000 (0.44%) with SCD had a discharge diagnosis of PE compared with 59,000 of 48,611,000 (0.12%) of African Americans without SCD. The prevalence of DVT was similar in patients < age 40 with SCD, 7000 of 1,581,000 (0.44%) and in African Americans who did not have SCD, 193,000 of 48,611,000 (0.40%).
CONCLUSION: The high prevalence of apparent PE in patients with SCD, compared with non-SCD African-American patients of the same age and the comparable prevalence of DVT in both groups are compatible with the concept that thrombosis in situ might be present in many. On the other hand, the data suggest that PE is not rare in patients with SCD. This suggests that PE might be an etiologic factor in patients with SCD who develop respiratory symptoms. In such patients, an imaging procedure might be appropriate.

Entities:  

Mesh:

Year:  2006        PMID: 17000225     DOI: 10.1016/j.amjmed.2006.08.015

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  64 in total

1.  Prospective study of sickle cell trait and venous thromboembolism incidence.

Authors:  A R Folsom; W Tang; N S Roetker; A V Kshirsagar; V K Derebail; P L Lutsey; R Naik; J S Pankow; M L Grove; S Basu; N S Key; M Cushman
Journal:  J Thromb Haemost       Date:  2014-12-11       Impact factor: 5.824

Review 2.  Hypercoagulability in congenital haemolytic anaemias.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2012-10-25       Impact factor: 3.443

3.  Abnormal Ventilation-Perfusion Scan Is Associated with Pulmonary Hypertension in Sickle Cell Adults.

Authors:  Alem Mehari; Norris Igbineweka; Darlene Allen; Jim Nichols; Swee Lay Thein; Nargues A Weir
Journal:  J Nucl Med       Date:  2018-06-07       Impact factor: 10.057

Review 4.  Hypercoagulability and thrombotic complications in hemolytic anemias.

Authors:  Kenneth I Ataga
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

5.  Racial and Ethnic Differences in Pediatric Pulmonary Hypertension: An Analysis of the Pediatric Pulmonary Hypertension Network Registry.

Authors:  Mei-Sing Ong; Steve Abman; Eric D Austin; Jeffrey A Feinstein; Rachel K Hopper; Usha S Krishnan; Mary P Mullen; Marc D Natter; J Usha Raj; Erika B Rosenzweig; Kenneth D Mandl
Journal:  J Pediatr       Date:  2019-06-05       Impact factor: 4.406

Review 6.  Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know.

Authors:  Rakhi P Naik; Michael B Streiff; Sophie Lanzkron
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

Review 7.  Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics.

Authors:  Zahra Pakbaz; Ted Wun
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

8.  Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort study.

Authors:  Megan Z Roberts; G Eric Gaskill; Julie Kanter-Washko; T Rogers Kyle; Brittany C Jones; Nicole M Bohm
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

9.  Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication.

Authors:  Rakhi P Naik; Michael B Streiff; Carlton Haywood; Julie A Nelson; Sophie Lanzkron
Journal:  Am J Med       Date:  2013-05       Impact factor: 4.965

10.  Evaluating the safety and effectiveness of venous thromboembolism prophylaxis in patients with sickle cell disease.

Authors:  Denise Kelley; Lauren Thornton Jones; Jun Wu; Nicole Bohm
Journal:  J Thromb Thrombolysis       Date:  2017-05       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.